Exercise of share options
(Oslo, Norway, 18 June 2015) The Board of Directors of Bionor Pharma ASA (OSE:BIONOR) has resolved to issue 666,667 new shares in the Company based on options exercised by former employee Birger Sørensen.
The new shares are issued at NOK 2.00 per share according to the option agreement. The share capital increase will be registered in the Companies Register as soon as practically possible.
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company's focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.
Bionor Pharma's current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma's current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.
Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.
More information about Bionor is available at www.bionorpharma.com.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For more information please contact:
Bionor Pharma ASA
Jørgen Fischer Ravn
Vice President for Investor Relations and Communications
Tel + 45 20 30 39 03